Sanofi India Ltd
Company Profile
Business description
Sanofi India Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It focuses on a range of therapeutic areas, including diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines, among others, and sells its products through independent distributors predominantly in India. The company's products are manufactured in different types of dosage forms, including tablets, capsules (hard and soft), Eye/Ear drops, ampoules, vials, creams, and ointments, and are marketed under different brand names such as Soframycin, Lantus, Cardace, Soliqua, Solian, Thyrogen, Telcite, Zolineg, etc. Geographically, the company generates a majority of its revenue from India, followed by Singapore, and other export markets.
Contact
Saki Vihar Road
Sanofi House, CTS Number 117-B
L&T Business Park
Powai
MumbaiMH400072
INDT: +91 2228032000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
1,285
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,001.40 | 59.90 | 0.67% |
CAC 40 | 7,827.34 | 82.93 | 1.07% |
DAX 40 | 24,214.87 | 172.97 | 0.72% |
Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
FTSE 100 | 9,058.27 | 34.46 | 0.38% |
HKSE | 25,490.47 | 360.44 | 1.43% |
NASDAQ | 20,892.69 | 81.49 | -0.39% |
Nikkei 225 | 41,171.32 | 1,396.40 | 3.51% |
NZX 50 Index | 12,794.06 | 39.68 | -0.31% |
S&P 500 | 6,309.62 | 4.02 | 0.06% |
S&P/ASX 200 | 8,737.20 | 60.00 | 0.69% |
SSE Composite Index | 3,582.30 | 0.44 | 0.01% |